Tesla Inc (NASDAQ:TSLA) shares fell more than 3% on Tuesday, pressured by a combination of legal setbacks, a price increase on its best-selling model and growing concern that an imminent SpaceX listing will draw investor capital away from the electric vehicle maker.
Much of the selling pressure has been building over the past week rather than from a single catalyst.
Amer Sports Inc (NYSE:AS) shares added almost 5% on Tuesday after the company reported first quarter 2026 results that beat analyst expectations on both revenue and earnings and raised its full-year outlook.
The company posted revenue of $1.95 billion for the quarter, up 32% year-over-year and ahead of the $1.83 billion consensus estimate. On a constant currency basis, revenue rose 26%.
NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offering, raising about $2 million in gross proceeds before fees and expenses.
The clinical-stage antiviral drug developer sold about 1.3 million shares of common stock, or pre-funded warrants in lieu of shares, along with accompanying warrants to purchase an additional roughly 1.3 million common shares.
Ideal Power Inc (NASDAQ:IPWR, FRA:5ILA) announced that it has closed its previously announced registered direct offering with certain institutional investors, raising about $30 million in gross proceeds before expenses.
The Austin, Texas-based company sold about 5.3 million shares of common stock, or common stock equivalents, in the offering. The securities were priced at the market under Nasdaq rules, according to the company.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that updated data from its Expanded Access Program showed intranasal foralumab continued to be well tolerated over extended treatment in patients with non-active secondary progressive multiple sclerosis (na-SPMS), with encouraging signs of disability stabilization and reduced fatigue.
The biotechnology company said data collected through March 2026, updated from an earlier March 2025 readout, covered 14 patients enrolled in the ongoing program evaluating foralumab, a fully human anti-CD3 monoclonal antibody administered intranasally.
Shares in Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF, FRA:T2X) rose 3% to 73.4p after it delivered higher first-quarter earnings as a much stronger realised gold price more than offset lower gold sales from its Segilola mine in Nigeria.
The London and Toronto-listed gold miner reported revenue of US$74.3mln for the three months to March 31, up from US$64.0mln a year earlier, while EBITDA rose to $55.8mln from $43.6mln.
Shares in IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and biomarker analytics specialist, rose as much as 11% after interim results showed the company's order book at its highest level since 2021, prompting its house broker to describe full-year estimates as conservative.
The company reported revenue up 23% to £3.9 million in the six months to 31 March, with gross margin improving to 53.2% from 49.6% as a higher proportion of analysis-related work, which carries stronger margins, came through the mix.